Clinical Trials Logo

Biliary Tract Cancer clinical trials

View clinical trials related to Biliary Tract Cancer.

Filter by:

NCT ID: NCT03475953 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

REGOMUNE
Start date: May 4, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial). Assessement of the efficacy and safety of a low-dose of regorafenib (80mg/day) with avelumab in patients with advanced or metastatic colorectal tumors.

NCT ID: NCT03311789 Recruiting - Clinical trials for Biliary Tract Cancer

Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs

Start date: May 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-arm, phase I/II trial in biliary tract cancer (BTC) patients. The purpose of this trial is to evaluate the safety and effect of PD-1 inhibitor in combination with gemcitabine/cisplatin chemotherapy in patients with advanced unresectable or metastatic BTCs. The primary objective: 6-month progression free survival (PFS). The second objectives: objective clinical response(according to RECIST version 1.1), safety, symptom control and quality of life (QoL) (according to EORTC QoL C30 and BIL 21), overall survival. The exploratory objectives: assessment of immunological response (cytokines, lymphocyte phenotype, immunoglobulins), and evaluation of pathological, immunological and clinical predictive factors for response/toxicity.

NCT ID: NCT03185988 Recruiting - Colorectal Cancer Clinical Trials

Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

Start date: July 1, 2017
Phase: Phase 2
Study type: Interventional

To seek the efficacy signals of trastuzumab in combination with chemotherapy in pretreated patients of HER2 positive, relapse or metastatic carcinoma of digestive system as response rate (RR) determined by the Investigator using RECIST 1.1, and provide evidence for phase III clinical trial.

NCT ID: NCT03144856 Recruiting - Clinical trials for Biliary Tract Cancer

Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers

Start date: February 22, 2017
Phase: Phase 2
Study type: Interventional

This study is designed to see whether Apatinib is effective in treating patients with advanced refractory biliary tract cancers.

NCT ID: NCT03110484 Recruiting - Clinical trials for Biliary Tract Cancer

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Start date: July 9, 2021
Phase: Phase 2
Study type: Interventional

Pemetrexed in combination with erlotinib as a salvage treatment in patients with metastatic biliary tract cancer (BTC) who failed gemcitabine containing chemotherapy

NCT ID: NCT02350686 Recruiting - Clinical trials for Biliary Tract Cancer

XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy

Start date: May 14, 2015
Phase: Phase 2
Study type: Interventional

Phase II study of second line capecitabine plus oxaliplatin (XELOX) in patients with advanced biliary tract carcinoma after failure of gemcitabine-based chemotherapy.

NCT ID: NCT01811277 Recruiting - Pancreatic Cancer Clinical Trials

SOX Sequential S-1 in Advanced Biliary Tract Carcinoma(BTC)and Pancreatic Cancer

Start date: July 2010
Phase: Phase 2
Study type: Interventional

This is an exploratory, single-armed, open label study on the efficacy and safety of sequential S-1 therapy after SOX in unresectable metastatic or locally advanced biliary system or periampullary cancer or pancreatic cancer patients. The primary endpoint is Objective response rate and secondary endpoint is progression free survival , overall survival ,1 year survival rate and safety.

NCT ID: NCT01494363 Recruiting - Clinical trials for Biliary Tract Cancer

Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer

Start date: October 2011
Phase: Phase 2
Study type: Interventional

1. Goals The primary goal of this phase II trial is to: evaluate the response rate of combination chemotherapy with Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan in patients with locally advanced or metastatic Biliary tract cancer as first-line chemotherapy Secondary goals are to: evaluate the treatment-related toxicities of this combination, investigate progression-free survival(PFS) and overall survival(OS) in this population 2. Design The proposed clinical trial is an open label, non-comparative, multicenter phase II trial according to the two stage testing design by Simon two-stage testing procedure

NCT ID: NCT01234051 Recruiting - Clinical trials for Biliary Tract Cancer

Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer

Start date: November 2010
Phase: Phase 2
Study type: Interventional

1. Goals - The primary goal of this phase II trial is to: evaluate the response rate of combination chemotherapy with docetaxel and oxaliplatin in patients with locally advanced or metastatic BTC as first-line therapy Secondary goals are to:evaluate the treatment-related toxicities of this combination, investigate progression-free survival (PFS) and overall survival (OS) in this population 2. Design The proposed clinical trial is an open label, non-comparative, multicenter phase II trial according to the two stage testing design by Simon.22